Skip to content
2000
Volume 4, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

The Gut Microbiota (GM) is gaining recognition for its important role in drug metabolism, significantly impacting the bioavailability, therapeutic efficacy, and toxicity of drugs. We describe how enzymes from gut microbes influence drug bioavailability, therapeutic outcomes, and possible adverse reactions, which contribute to considerable individual differences in drug responses. According to microbiome studies, including metagenomic sequencing, cutting-edge models, and bioinformatics approaches, intricate interactions between the microbiota and drugs are being revealed, paving the way for personalized therapeutic strategies. Additionally, this review describes therapeutic approaches aimed at altering GM composition, such as probiotics, prebiotics, and fecal microbiota transplantation, to enhance the effectiveness of drugs and reduce the risk of toxicity. Beyond scientific findings, we also focus on the regulatory and clinical implications, emphasizing the need for a structured framework that integrates microbiota-related considerations into drug development and treatment. As pharmacomicrobiomics advances, incorporating microbiome profiling into clinical practice holds promise for enhancing the efficacy and safety of drug treatments. Ultimately, this review seeks to deepen understanding of the GM’s influence on drug metabolism, supporting a transition towards microbiome-informed precision medicine and promoting tailored, safer healthcare solutions that meet the needs of diverse patient populations as well as gut microbiome's structure, composition, and dynamic roles which emphasizes its enzymatic diversity and metabolic pathways that aid in drug transformation and affect pharmacokinetics in conjunction with traditional liver functions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906374737250901101633
2025-05-04
2026-02-25

  • From This Site

    /content/journals/ijghd/10.2174/0126662906374737250901101633
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WanY. ZuoT. Interplays between drugs and the gut microbiome.Gastroenterol. Rep. (Oxf.)202210goac00910.1093/gastro/goac009 35401987
     [Google Scholar]
  2. DhurjadP. DhavalikerC. GuptaK. SontiR. Exploring drug metabolism by the gut microbiota: modes of metabolism and experimental approaches.Drug Metab. Dispos.202250322423410.1124/dmd.121.000669 34969660
     [Google Scholar]
  3. ThursbyE. JugeN. Introduction to the human gut microbiota.Biochem. J.2017474111823183610.1042/BCJ20160510 28512250
     [Google Scholar]
  4. PantA. MaitiT.K. MahajanD. DasB. Human gut microbiota and drug metabolism.Microb. Ecol.20238619711110.1007/s00248‑022‑02081‑x 35869999
     [Google Scholar]
  5. XieY. HuF. XiangD. LuH. LiW. ZhaoA. HuangL. WangR. The metabolic effect of gut microbiota on drugs.Drug Metab. Rev.202052113915610.1080/03602532.2020.1718691 32116054
     [Google Scholar]
  6. ZhaoQ. ChenY. HuangW. ZhouH. ZhangW. Drug-microbiota interactions: An emerging priority for precision medicine.Signal Transduct. Target. Ther.20238138610.1038/s41392‑023‑01619‑w 37806986
     [Google Scholar]
  7. RautavaS. LuotoR. SalminenS. IsolauriE. Microbial contact during pregnancy, intestinal colonization and human disease.Nat. Rev. Gastroenterol. Hepatol.201291056557610.1038/nrgastro.2012.144 22890113
     [Google Scholar]
  8. Nuriel-OhayonM. NeumanH. KorenO. Microbial changes during pregnancy, birth, and infancy.Front. Microbiol.20167103110.3389/fmicb.2016.01031 27471494
     [Google Scholar]
  9. RodríguezJ.M. MurphyK. StantonC. RossR.P. KoberO.I. JugeN. AvershinaE. RudiK. NarbadA. JenmalmM.C. MarchesiJ.R. ColladoM.C. The composition of the gut microbiota throughout life, with an emphasis on early life.Microb. Ecol. Health Dis.20152602605010.3402/mehd.v26.26050 25651996
     [Google Scholar]
  10. ValdesA.M. WalterJ. SegalE. SpectorT.D. Role of the gut microbiota in nutrition and health.BMJ2018361k217910.1136/bmj.k2179 29899036
     [Google Scholar]
  11. HouK. WuZ.X. ChenX.Y. WangJ.Q. ZhangD. XiaoC. ZhuD. KoyaJ.B. WeiL. LiJ. ChenZ.S. Microbiota in health and diseases.Signal Transduct. Target. Ther.20227113510.1038/s41392‑022‑00974‑4 35461318
     [Google Scholar]
  12. JandhyalaS.M. TalukdarR. SubramanyamC. VuyyuruH. SasikalaM. Nageshwar ReddyD. Role of the normal gut microbiota.World J. Gastroenterol.201521298787880310.3748/wjg.v21.i29.8787 26269668
     [Google Scholar]
  13. AfzaalM. SaeedF. ShahY.A. HussainM. RabailR. SocolC.T. HassounA. PateiroM. LorenzoJ.M. RusuA.V. AadilR.M. Human gut microbiota in health and disease: Unveiling the relationship.Front. Microbiol.20221399900110.3389/fmicb.2022.999001 36225386
     [Google Scholar]
  14. Phang-LynS. LlerenaV.A. Biochemistry, biotransformation. In:StatPearls.StatPearls Publishing2024
     [Google Scholar]
  15. ZimmermannM. Zimmermann-KogadeevaM. WegmannR. GoodmanA.L. Mapping human microbiome drug metabolism by gut bacteria and their genes.Nature2019570776246246710.1038/s41586‑019‑1291‑3 31158845
     [Google Scholar]
  16. BlautM. Ecology and physiology of the intestinal tract.Curr. Top. Microbiol. Immunol.201124727210.1007/82_2011_192
     [Google Scholar]
  17. ShuaibF. AliA. KhanI. AhmadA. KhanZ. Amanullah, Influence of gut microbiota on drug metabolism and therapeutic efficacy.S. East. Eur. J. Public Health20242191–52191219510.70135/seejph.vi.2352
     [Google Scholar]
  18. BaiX. LiuG. YangJ. ZhuJ. LiX. Gut microbiota as the potential mechanism to mediate drug metabolism under high-altitude hypoxia.Curr. Drug Metab.202223182010.2174/1389200223666220128141038 35088664
     [Google Scholar]
  19. SeshadriS. GajjarD. JoshiA. BhatiaZ. KumarS. Understanding and role of gut microbiota on drug response and toxicity.J. Toxicol. Stud.202422125210.59400/jts.v2i2.1252
     [Google Scholar]
  20. SousaT. PatersonR. MooreV. CarlssonA. AbrahamssonB. BasitA.W. The gastrointestinal microbiota as a site for the biotransformation of drugs.Int. J. Pharm.20083631-212510.1016/j.ijpharm.2008.07.009 18682282
     [Google Scholar]
  21. JimonetP. DruartC. Blanquet-DiotS. BoucinhaL. KourulaS. Le VaconF. MaubantS. RabotS. Van de WieleT. SchurenF. ThomasV. WaltherB. ZimmermannM. Gut microbiome integration in drug discovery and development of small molecules.Drug Metab. Dispos.202452427428710.1124/dmd.123.001605 38307852
     [Google Scholar]
  22. WeersmaR.K. ZhernakovaA. FuJ. Interaction between drugs and the gut microbiome.Gut20206981510151910.1136/gutjnl‑2019‑320204 32409589
     [Google Scholar]
  23. DikeochaI.J. Al-KabsiA.M. MiftahussururM. AlshawshM.A. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.FASEB J.2022366e2235010.1096/fj.202101986R 35579628
     [Google Scholar]
  24. ShayeganpourA. Capacity of the Human Gut Microbiome in Metabolism of Drugs and Its Interaction with CYP450 Enzymes.Intechopen202410.5772/intechopen.112940
     [Google Scholar]
  25. PellockS.J. RedinboM.R. Glucuronides in the gut: Sugar-driven symbioses between microbe and host.J. Biol. Chem.2017292218569857610.1074/jbc.R116.767434 28389557
     [Google Scholar]
  26. PolletR.M. D’AgostinoE.H. WaltonW.G. XuY. LittleM.S. BiernatK.A. PellockS.J. PattersonL.M. CreekmoreB.C. IsenbergH.N. BahethiR.R. BhattA.P. LiuJ. GharaibehR.Z. RedinboM.R. an atlas of β-glucuronidases in the human intestinal microbiome.structure2017257967977.e510.1016/j.str.2017.05.003 28578872
     [Google Scholar]
  27. WilsonI.D. NicholsonJ.K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity.Transl. Res.201717920422210.1016/j.trsl.2016.08.002 27591027
     [Google Scholar]
  28. CrouwelF. BuiterH.J.C. de BoerN.K. Gut microbiota-driven drug metabolism in inflammatory bowel disease.J. Crohn’s Colitis202115230731510.1093/ecco‑jcc/jjaa143 32652007
     [Google Scholar]
  29. KoppelN. BisanzJ. TurnbaughP. BalskusE.P. Characterization of a cardiac drug‐inactivating enzyme from the prominent human gut microbe, Eggerthella lenta.FASEB J.201731S110.1096/fasebj.31.1_supplement.608.3
     [Google Scholar]
  30. TianJ. LiC. DongZ. YangY. XingJ. YuP. XinY. XuF. WangL. MuY. GuoX. SunQ. ZhaoG. GuY. QinG. JiangW. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation.Nat. Metab.20235589690910.1038/s42255‑023‑00796‑w 37157031
     [Google Scholar]
  31. KimD.H. Interaction of drugs with gut microbiota modulators.Drug Metab. Rev.202355318119410.1080/03602532.2023.2197178 36999361
     [Google Scholar]
  32. MousaS. SarfrazM. MousaW.K. The interplay between gut microbiota and oral medications and its impact on advancing precision medicine.Metabolites202313567410.3390/metabo13050674 37233715
     [Google Scholar]
  33. TsunodaS.M. GonzalesC. JarmuschA.K. MomperJ.D. MaJ.D. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability.Clin. Pharmacokinet.202160897198410.1007/s40262‑021‑01032‑y 33959897
     [Google Scholar]
  34. ErvinS.M. SimpsonJ.B. GibbsM.E. CreekmoreB.C. LimL. WaltonW.G. GharaibehR.Z. RedinboM.R. Structural Insights into endobiotic reactivation by human gut microbiome-encoded sulfatases.Biochemistry202059403939395010.1021/acs.biochem.0c00711 32993284
     [Google Scholar]
  35. LiS. ZhuS. YuJ. The role of gut microbiota and metabolites in cancer chemotherapy.J. Adv. Res.20246422323510.1016/j.jare.2023.11.027 38013112
     [Google Scholar]
  36. IlinaE.N. MayorovaE.M. ManolovA.I. KorenkovaA.A. BahmetjevV.V. GorbunovK.S. Gut microbiome and drug metabolism.Biomedical Chemistry: Research and Methods202141e0014610.18097/BMCRM00146
     [Google Scholar]
  37. DoddD. CannI. Tutorial: Microbiome studies in drug metabolism.Clin. Transl. Sci.202215122812283710.1111/cts.13416 36099474
     [Google Scholar]
  38. YangH. ZhangY. ZhouR. WuT. ZhuP. LiuY. ZhouJ. XiongY. XiongY. ZhouH. ZhangW. ShuY. LiX. LiQ. Antibiotics-induced depletion of rat microbiota induces changes in the expression of host drug-processing genes and pharmacokinetic behaviors of cyps probe drugs.Drug Metab. Dispos.202351450952010.1124/dmd.122.001173 36623881
     [Google Scholar]
  39. TogaoM. KurakawaT. TajimaS. WagaiG. Ohta-TakadaY. OtsukaJ. KuritaA. KawakamiK. Human gut microbiota influences drug-metabolizing enzyme hepatic Cyp3a: A human flora-associated mice study.J. Toxicol. Sci.202348633334310.2131/jts.48.333 37258238
     [Google Scholar]
  40. ZemanováN. LněničkováK. VavrečkováM. AnzenbacherováE. AnzenbacherP. ZapletalováI. HermanováP. HudcovicT. KozákováH. JourováL. Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression.PLoS One20211611e025964310.1371/journal.pone.0259643 34752478
     [Google Scholar]
  41. ShahidA. HayatS. MunirS. AshfaqU.A. KhanA.A. BilalM. Modulation of human microbiome and drug metabolism. In:Biochemistry of Drug Metabolizing Enzymes.Elsevier202237539710.1016/B978‑0‑323‑95120‑3.00012‑9
     [Google Scholar]
  42. JourováL. VavreckovaM. ZemanovaN. AnzenbacherP. LangovaK. HermanovaP. HudcovicT. AnzenbacherovaE. Gut microbiome alters the activity of liver cytochromes P450 in mice with sex-dependent differences.Front. Pharmacol.2020110130310.3389/fphar.2020.01303 33123003
     [Google Scholar]
  43. DvořákZ. LiH. ManiS. Microbial metabolites as ligands to xenobiotic receptors: Chemical mimicry as potential drugs of the future.Drug Metab. Dispos.202351221922710.1124/dmd.122.000860 36184080
     [Google Scholar]
  44. WangJ. ZhouT. Unveiling gut microbiota’s role: Bidirectional regulation of drug transport for improved safety.Med. Res. Rev.202545131134310.1002/med.22077 39180410
     [Google Scholar]
  45. VerdegaalA.A. GoodmanA.L. Integrating the gut microbiome and pharmacology.Sci. Transl. Med.202416732eadg835710.1126/scitranslmed.adg8357 38295186
     [Google Scholar]
  46. LiuM. XuJ. JinQ. LiY. Interaction of intestinal microbiota with medications.Curr. Drug Metab.202324855456710.2174/1389200224666230418104540 37073652
     [Google Scholar]
  47. Álvarez-MercadoA.I. Navarro-OliverosM. Robles-SánchezC. Plaza-DíazJ. Sáez-LaraM.J. Muñoz-QuezadaS. FontanaL. Abadía-MolinaF. Microbial population changes and their relationship with human health and disease.Microorganisms2019736810.3390/microorganisms7030068 30832423
     [Google Scholar]
  48. WangB. YaoM. LvL. LingZ. LiL. The human microbiota in health and disease.Engineering (Beijing)201731718210.1016/J.ENG.2017.01.008
     [Google Scholar]
  49. BoulangéC.L. NevesA.L. ChillouxJ. NicholsonJ.K. DumasM.E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease.Genome Med.2016814210.1186/s13073‑016‑0303‑2 27098727
     [Google Scholar]
  50. HurK.Y. LeeM.S. Gut microbiota and metabolic disorders.Diabetes Metab. J.201539319820310.4093/dmj.2015.39.3.198 26124989
     [Google Scholar]
  51. Angoa-PérezM. ZagoracB. FrancescuttiD.M. ShafferZ.D. TheisK.R. KuhnD.M. Cocaine hydrochloride, cocaine methiodide and methylenedioxypyrovalerone (MDPV) cause distinct alterations in the structure and composition of the gut microbiota.Sci. Rep.20231311375410.1038/s41598‑023‑40892‑1 37612353
     [Google Scholar]
  52. KhanI. Drugs and gut microbiome interactions—an emerging field of tailored medicine.BMC Pharmacol. Toxicol.20232414310.1186/s40360‑023‑00684‑9 37649091
     [Google Scholar]
  53. WippermanM.F. FitzgeraldD.W. JusteM.A.J. TaurY. NamasivayamS. SherA. BeanJ.M. BucciV. GlickmanM.S. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed.Sci. Rep.2017711076710.1038/s41598‑017‑10346‑6 28883399
     [Google Scholar]
  54. EriboO.A. du PlessisN. OzturkM. GulerR. WalzlG. ChegouN.N. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?Cell. Mol. Life Sci.20207781497150910.1007/s00018‑019‑03370‑4 31729564
     [Google Scholar]
  55. PallejaA. MikkelsenK.H. ForslundS.K. KashaniA. AllinK.H. NielsenT. HansenT.H. LiangS. FengQ. ZhangC. PylP.T. CoelhoL.P. YangH. WangJ. TypasA. NielsenM.F. NielsenH.B. BorkP. WangJ. VilsbøllT. HansenT. KnopF.K. ArumugamM. PedersenO. Recovery of gut microbiota of healthy adults following antibiotic exposure.Nat. Microbiol.20183111255126510.1038/s41564‑018‑0257‑9 30349083
     [Google Scholar]
  56. Vich VilaA. CollijV. SannaS. SinhaT. ImhannF. BourgonjeA.R. MujagicZ. JonkersD.M.A.E. MascleeA.A.M. FuJ. KurilshikovA. WijmengaC. ZhernakovaA. WeersmaR.K. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.Nat. Commun.202011136210.1038/s41467‑019‑14177‑z 31953381
     [Google Scholar]
  57. DegraeveA.L. HaufroidV. LoriotA. GattoL. AndriesV. VereeckeL. ElensL. BindelsL.B. Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1.Microbiome202311113810.1186/s40168‑023‑01578‑y 37408070
     [Google Scholar]
  58. MohamedM.E. SaqrA. StaleyC. OnyeaghalaG. TeigenL. DorrC.R. RemmelR.P. GuanW. OettingW.S. MatasA.J. IsraniA.K. JacobsonP.A. Pharmacomicrobiomics: Immunosuppressive drugs and microbiome interactions in transplantation.Transplantation202410891895191010.1097/TP.0000000000004926 38361239
     [Google Scholar]
  59. CooperD.A. BhushanA. Bacterial influence on pharmacokinetics of tacrolimus and sulfasalazine through regulation of host metabolism.Adv. Ther. (Weinh.)202478230044910.1002/adtp.202300449
     [Google Scholar]
  60. Zimmermann-KogadeevaM. ZimmermannM. GoodmanA.L. Insights from pharmacokinetic models of host-microbiome drug metabolism.Gut Microbes202011358759610.1080/19490976.2019.1667724 31564204
     [Google Scholar]
  61. Džidić-KrivićA. KusturicaJ. SherE.K. SelakN. OsmančevićN. Karahmet FarhatE. SherF. Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs.Drug Metab. Rev.2023551-212613910.1080/03602532.2023.2186313 36916327
     [Google Scholar]
  62. LiH. HeJ. JiaW. The influence of gut microbiota on drug metabolism and toxicity.Expert Opin. Drug Metab. Toxicol.2016121314010.1517/17425255.2016.1121234 26569070
     [Google Scholar]
  63. PrukpitikulP. SirivarasaiJ. SutjaritN. The molecular mechanisms underlying gut microbiota-miRNA interaction in metabolic disorders.Benef. Microbes2024151839610.1163/18762891‑20230103 38350488
     [Google Scholar]
  64. ZhangC. LiuH. SunL. WangY. ChenX. DuJ. SjölingÅ. YaoJ. WuS. An overview of host‐derived molecules that interact with gut microbiota.iMeta202322e8810.1002/imt2.88 38868433
     [Google Scholar]
  65. WangS. GongX. XiaoF. YangY. Recent advances in host-focused molecular tools for investigating host-gut microbiome interactions.Front. Microbiol.202415133503610.3389/fmicb.2024.1335036 38605718
     [Google Scholar]
  66. FernandesC. MirandaM.C.C. RoqueC.R. PaguadaA.L.P. MotaC.A.R. FlorêncioK.G.D. PereiraA.F. WongD.V.T. OriáR.B. Lima-JúniorR.C.P. Is There an interplay between environmental factors, microbiota imbalance, and cancer chemotherapy-associated intestinal mucositis?Pharmaceuticals (Basel)2024178102010.3390/ph17081020 39204125
     [Google Scholar]
  67. FanJ. JiangT. HeD. Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Front. Immunol.202314118903610.3389/fimmu.2023.1189036 37841256
     [Google Scholar]
  68. SirajS. Role of microbiome in personalized medicine.Precision Med. Commun2023327910.55627/pmc.003.02.0480
     [Google Scholar]
  69. ShenS. WangJ. MaC. ChenY. DingH. ZhangJ. Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and] in vivo.Microbiome202311120910.1186/s40168‑023‑01658‑z 37749663
     [Google Scholar]
  70. YoonS. Interaction between gut microbiome and drugs in companion animals: Translational aspects.Korean Society Veter Nursing20243111110.56878/jvn.2024.3.1.1
     [Google Scholar]
  71. KangM.J. KimH.G. KimJ.S. OhD.G. UmY.J. SeoC.S. HanJ.W. ChoH.J. KimG.H. JeongT.C. JeongH.G. The effect of gut microbiota on drug metabolism.Expert Opin. Drug Metab. Toxicol.20139101295130810.1517/17425255.2013.807798 24033282
     [Google Scholar]
  72. KyriachenkoY. FalalyeyevaT. KorotkyiO. MolochekN. KobyliakN. Crosstalk between gut microbiota and antidiabetic drug action.World J. Diabetes201910315416810.4239/wjd.v10.i3.154 30891151
     [Google Scholar]
  73. van de SteegE. SchurenF.H.J. ObachR.S. van WoudenberghC. WalkerG.S. HeerikhuisenM. NooijenI.H.G. VaesW.H.J. An ex vivo fermentation screening platform to study drug metabolism by human gut microbiota.Drug Metab. Dispos.201846111596160710.1124/dmd.118.081026 30158249
     [Google Scholar]
  74. MorteléO. IturrospeE. BreynaertA. VerdicktE. XavierB.B. LammensC. Malhotra-KumarS. JorensP.G. PietersL. van NuijsA.L.N. HermansN. Optimization of an in vitro gut microbiome biotransformation platform with chlorogenic acid as model compound: From fecal sample to biotransformation product identification.J. Pharm. Biomed. Anal.201917511276810.1016/j.jpba.2019.07.016 31398630
     [Google Scholar]
  75. PolettiM. ArnautsK. FerranteM. KorcsmarosT. Organoid-based models to study the role of host-microbiota interactions in IBD.J. Crohn’s Colitis20211571222123510.1093/ecco‑jcc/jjaa257 33341879
     [Google Scholar]
  76. ZietekT. GiesbertzP. EwersM. ReichartF. WeinmüllerM. UrbauerE. HallerD. DemirI.E. CeyhanG.O. KesslerH. RathE. Organoids to study intestinal nutrient transport, drug uptake and metabolism – update to the human model and expansion of applications.Front. Bioeng. Biotechnol.2020857765610.3389/fbioe.2020.577656 33015026
     [Google Scholar]
  77. BozzettiV. SengerS. Organoid technologies for the study of intestinal microbiota–host interactions.Trends Mol. Med.202228429030310.1016/j.molmed.2022.02.001 35232671
     [Google Scholar]
  78. WaclawikováB. CoduttiA. AlimK. El AidyS. Gut microbiota-motility interregulation: Insights from in vivo, ex vivo and in silico studies.Gut Microbes2022141199729610.1080/19490976.2021.1997296 34978524
     [Google Scholar]
  79. LinW. ChenY. UnadkatJ.D. ZhangX. WuD. HeimbachT. Applications, challenges, and outlook for PBPK modeling and simulation: A regulatory, industrial and academic perspective.Pharm. Res.20223981701173110.1007/s11095‑022‑03274‑2 35552967
     [Google Scholar]
  80. YangY. ChenY. WangL. XuS. FangG. GuoX. ChenZ. GuZ. PBPK modeling on organs-on-chips: An overview of recent advancements.Front. Bioeng. Biotechnol.20221090048110.3389/fbioe.2022.900481 35497341
     [Google Scholar]
  81. SonJ.W. ShoaieS. LeeS. Systems biology: A multi-omics integration approach to metabolism and the microbiome.Endocrinol. Metab. (Seoul)202035350751410.3803/EnM.2020.303 32981293
     [Google Scholar]
  82. KolliU. JalodiaR. MoidunnyS. SinghP.K. BanY. TaoJ. CantuG.N. ValdesE. RamakrishnanS. RoyS. Multi-omics analysis revealing the interplay between gut microbiome and the host following opioid use.Gut Microbes2023152224618410.1080/19490976.2023.2246184 37610102
     [Google Scholar]
  83. WuJ. SingletonS.S. BhuiyanU. KrammerL. MazumderR. Multi-omics approaches to studying gastrointestinal microbiome in the context of precision medicine and machine learning.Front. Mol. Biosci.202410133737310.3389/fmolb.2023.1337373 38313584
     [Google Scholar]
  84. DaliriE.B.M. OfosuF.K. ChelliahR. LeeB.H. OhD.H. Challenges and perspective in integrated multi-omics in gut microbiota studies.Biomolecules202111230010.3390/biom11020300 33671370
     [Google Scholar]
  85. WangS. JuD. ZengX. Mechanisms and clinical implications of human gut microbiota-drug interactions in the precision medicine era.Biomedicines202412119410.3390/biomedicines12010194 38255298
     [Google Scholar]
  86. NarlaD. SarellaP.N.K. Advances in analytical techniques for personalized medicine. In:Futuristic Trends in Pharmacy and Nursing; Iterative International Publishers (IIP)202420121210.58532/V3BGPN19P2CH5
     [Google Scholar]
  87. ShuklaV. SinghS. VermaS. VermaS. RizviA.A. AbbasM. Targeting the microbiome to improve human health with the approach of personalized medicine: Latest aspects and current updates.Clin. Nutr. ESPEN20246381382010.1016/j.clnesp.2024.08.005 39178987
     [Google Scholar]
  88. ChaudhariA. DwivediM.K. The concept of probiotics, prebiotics, postbiotics, synbiotics, nutribiotics, and pharmabiotics. In:Probiotics in the Prevention and Management of Human Diseases.Elsevier202211110.1016/B978‑0‑12‑823733‑5.00013‑1
     [Google Scholar]
  89. PurdelC. UngurianuA. Adam-DimaI. MarginăD. Exploring the potential impact of probiotic use on drug metabolism and efficacy.Biomed. Pharmacother.202316111446810.1016/j.biopha.2023.114468 36868015
     [Google Scholar]
  90. OhK.K. GuptaH. MinB.H. GanesanR. SharmaS.P. WonS.M. JeongJ.J. LeeS.B. ChaM.G. KwonG.H. JeongM.K. HyunJ.Y. EomJ.A. ParkH.J. YoonS.J. ChoiM.R. KimD.J. SukK.T. Elucidation of prebiotics, probiotics, postbiotics, and target from gut microbiota to alleviate obesity via network pharmacology study.Cells20221118290310.3390/cells11182903 36139478
     [Google Scholar]
  91. ScarpelliniE. RinninellaE. BasilicoM. ColomierE. RasettiC. LarussaT. SantoriP. AbenavoliL. From Pre- and probiotics to post-biotics: A narrative review.Int. J. Environ. Res. Public Health20211913710.3390/ijerph19010037 35010297
     [Google Scholar]
  92. MinkoffN.Z. AslamS. MedinaM. Tanner-SmithE.E. ZackularJ.P. AcraS. NicholsonM.R. ImdadA. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).Cochrane Libr.202320234CD01387110.1002/14651858.CD013871.pub2 37096495
     [Google Scholar]
  93. KhorutsA. StaleyC. SadowskyM.J. Faecal microbiota transplantation for Clostridioides difficile: Mechanisms and pharmacology.Nat. Rev. Gastroenterol. Hepatol.2021181678010.1038/s41575‑020‑0350‑4 32843743
     [Google Scholar]
  94. FlowersS.A. BhatS. LeeJ.C. Potential implications of gut microbiota in drug pharmacokinetics and bioavailability.Pharmacotherapy202040770471210.1002/phar.2428 32463481
     [Google Scholar]
  95. ZhengL. JiY.Y. WenX.L. DuanS.L. Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives.World J. Gastroenterol.202228232546256010.3748/wjg.v28.i23.2546 35949351
     [Google Scholar]
  96. El HouariA. EcaleF. MercierA. CrapartS. LaparreJ. SoulardB. RamnathM. BerjeaudJ.M. RodierM.H. CrépinA. Development of an in vitro model of human gut microbiota for screening the reciprocal interactions with antibiotics, drugs, and xenobiotics.Front. Microbiol.20221382835910.3389/fmicb.2022.828359 35495704
     [Google Scholar]
  97. KonstantinidisT. TsigalouC. KarvelasA. StavropoulouE. VoidarouC. BezirtzoglouE. Effects of antibiotics upon the gut microbiome: A review of the literature.Biomedicines202081150210.3390/biomedicines8110502 33207631
     [Google Scholar]
  98. MuC. ZhuW. Antibiotic effects on gut microbiota, metabolism, and beyond.Appl. Microbiol. Biotechnol.201910323-249277928510.1007/s00253‑019‑10165‑x 31701196
     [Google Scholar]
  99. LiL. YangX. TranD. SeoS.K. LuY. Combined oral contraceptives as victims of drug interactions.Drug Metab. Dispos.202351671873210.1124/dmd.122.000854 36963837
     [Google Scholar]
  100. AronsonJ.K. FernerR.E. Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives.BMJ Evid. Based Med.202126311211310.1136/bmjebm‑2020‑111363 32817012
     [Google Scholar]
  101. YadavN. ThakurA.K. ShekharN. Ayushi, Potential of antibiotics for the treatment and management of Parkinson’s disease: An overview.Curr. Drug Res. Rev.202113316617110.2174/2589977513666210315095133 33719951
     [Google Scholar]
  102. ZhongZ. YeM. YanF. A review of studies on gut microbiota and levodopa metabolism.Front. Neurol.202314104691010.3389/fneur.2023.1046910 37332996
     [Google Scholar]
  103. XuK. ShengS. ZhangF. Relationship between gut bacteria and levodopa metabolism.Curr. Neuropharmacol.20232171536154710.2174/1570159X21666221019115716 36278467
     [Google Scholar]
  104. MelisM. VascellariS. SantoruM.L. OppoV. FabbriM. SarchiotoM. MurgiaD. ZibettiM. LopianoL. SerraA. PalmasV. PisanuS. PerraD. MadauV. CusanoR. UvaP. MereuA. ContuP. MorelliM. AtzoriL. MelisM. ManzinA. CossuG. Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel.Eur. J. Neurol.20212841198120910.1111/ene.14644 33185912
     [Google Scholar]
  105. AzizR.K. HegazyS.M. YasserR. RizkallahM.R. ElRakaibyM.T. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug–microbiome interactions.Expert Opin. Drug Metab. Toxicol.201814101043105510.1080/17425255.2018.1530216 30269615
     [Google Scholar]
  106. Pharmacomicrobiomics: The universe of microbiome-drug interactions - Microbiome Times Magazine2024Available from:https://www.microbiometimes.com/pharmacomicrobiomics-the-universe-of-microbiome-drug-interactions/
  107. Torres-CarrilloN. Martínez-LópezE. Torres-CarrilloN.M. López-QuinteroA. Moreno-OrtizJ.M. González-MercadoA. Gutiérrez-HurtadoI.A. Pharmacomicrobiomics and drug–infection interactions: The impact of commensal, symbiotic and pathogenic microorganisms on a host response to drug therapy.Int. J. Mol. Sci.202324231710010.3390/ijms242317100 38069427
     [Google Scholar]
  108. DoestzadaM. VilaA.V. ZhernakovaA. KoonenD.P.Y. WeersmaR.K. TouwD.J. KuipersF. WijmengaC. FuJ. Pharmacomicrobiomics: A novel route towards personalized medicine?Protein Cell20189543244510.1007/s13238‑018‑0547‑2 29705929
     [Google Scholar]
  109. Infecting gut microbes with CRISPR-loaded virus demonstrates potential for microbiome gene editing2024Available from: https://www.ucsf.edu/news/2021/11/421846/infecting-gut-microbes-crispr-loaded-virus-demonstrates-potential-microbiome
  110. BrödelA.K. CharpenayL.H. GaltierM. FucheF.J. TerrasseR. PoquetC. HavránekJ. PignottiS. KrawczykA. ArraouM. PrevotG. SpadoniD. YarnallM.T.N. HesselE.M. Fernandez-RodriguezJ. DuportetX. BikardD. In situ targeted base editing of bacteria in the mouse gut.Nature2024632802687788410.1038/s41586‑024‑07681‑w 38987595
     [Google Scholar]
  111. ArnoldJ. GlazierJ. MimeeM. Genetic engineering of resident bacteria in the gut microbiome.J. Bacteriol.20232057e00127e2310.1128/jb.00127‑23 37382533
     [Google Scholar]
  112. RamachandranG. BikardD. Editing the microbiome the CRISPR way.Philos. Trans R Soc. Lond B Biol. Sci201937417722018010310.1098/rstb.2018.0103 30905295
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906374737250901101633
Loading
Beyond the Liver: Exploring Gut Microbiota Driven Drug Metabolism and Personalized Therapeutics
Int J Gastroenterol Hepatol Dis 4, E26662906374737 (2025); https://doi.org/10.2174/0126662906374737250901101633
/content/journals/ijghd/10.2174/0126662906374737250901101633
/content/journals/ijghd/10.2174/0126662906374737250901101633
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): drug metabolism; Gut microbiota; microbiome-drug interactions; pharmacokinetics; pharmacomicrobiomics; precision medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test